SG11201408330XA - Compositions and methods related to prevention and treatment of rabies infection - Google Patents
Compositions and methods related to prevention and treatment of rabies infectionInfo
- Publication number
- SG11201408330XA SG11201408330XA SG11201408330XA SG11201408330XA SG11201408330XA SG 11201408330X A SG11201408330X A SG 11201408330XA SG 11201408330X A SG11201408330X A SG 11201408330XA SG 11201408330X A SG11201408330X A SG 11201408330XA SG 11201408330X A SG11201408330X A SG 11201408330XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- beijing
- prevention
- road
- treatment
- Prior art date
Links
- 206010037742 Rabies Diseases 0.000 title abstract 3
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 241000711798 Rabies lyssavirus Species 0.000 abstract 1
- 239000012620 biological material Substances 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/076012 WO2013174003A1 (fr) | 2012-05-24 | 2012-05-24 | Compositions et procédés associés à la prévention et au traitement d'une infection rabique |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408330XA true SG11201408330XA (en) | 2015-01-29 |
Family
ID=49623026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408330XA SG11201408330XA (en) | 2012-05-24 | 2012-05-24 | Compositions and methods related to prevention and treatment of rabies infection |
Country Status (12)
Country | Link |
---|---|
US (1) | US9290564B2 (fr) |
EP (2) | EP2855521A4 (fr) |
JP (1) | JP5868549B2 (fr) |
KR (1) | KR101937733B1 (fr) |
CN (1) | CN104603149B (fr) |
BR (1) | BR112014029274B1 (fr) |
HK (1) | HK1210187A1 (fr) |
IN (1) | IN2014KN02831A (fr) |
MX (1) | MX369626B (fr) |
PH (1) | PH12014502628B1 (fr) |
SG (1) | SG11201408330XA (fr) |
WO (1) | WO2013174003A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5868549B2 (ja) * | 2012-05-24 | 2016-02-24 | マウントゲイト グループ リミテッド | 狂犬病感染の予防および治療に関する組成物および方法 |
CN104193823B (zh) * | 2014-08-22 | 2019-06-11 | 兰州生物制品研究所有限责任公司 | 一种抗狂犬病病毒特异性人源抗体及应用 |
TW201609152A (zh) | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
BR112017010298B1 (pt) * | 2014-11-18 | 2023-10-31 | Humabs Biomed Sa | Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, usos dos mesmos, molécula de ácido nucleico, vetor, célula isolada, composição farmacêutica, e kit de partes |
WO2017027805A1 (fr) * | 2015-08-13 | 2017-02-16 | University Of Massachusetts | Anticorps humains dirigés contre la rage et utilisations de ces derniers |
DK3458478T3 (da) | 2016-05-18 | 2021-03-22 | Boehringer Ingelheim Int | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling |
KR101990795B1 (ko) * | 2017-12-07 | 2019-06-19 | 대한민국 | 광견병바이러스 특이 항체 및 이를 이용한 광견병바이러스 검출방법 |
CN109970852B (zh) * | 2019-04-01 | 2020-10-13 | 浙江大学 | 分泌抗狂犬病毒m蛋白单克隆抗体的杂交瘤细胞株及应用 |
CN111171145B (zh) * | 2020-01-21 | 2021-11-05 | 兰州生物制品研究所有限责任公司 | 一种抗狂犬病病毒单克隆抗体、制备方法及用途 |
CN111888470A (zh) * | 2020-08-12 | 2020-11-06 | 赵静 | 具有中和狂犬病病毒效能的冲洗液及其活性检测方法 |
WO2023215746A2 (fr) * | 2022-05-02 | 2023-11-09 | Javelin Oncology, Inc. | Anticorps anti-alppl2 et récepteurs antigéniques chimériques, et compositions et méthodes d'utilisation |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5028530A (en) | 1985-01-28 | 1991-07-02 | Xoma Corporation | AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques |
CH0229046H1 (de) | 1985-03-30 | 1998-07-15 | Stuart Alan Kauffman | Method for obtaining dna, rna, peptides, polypeptinique. des or proteins by means of a dna recombinant tech |
EP0232262A4 (fr) | 1985-08-15 | 1989-09-19 | Stauffer Chemical Co | Microorganisme producteur de tryptophane. |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
EP0832981A1 (fr) | 1987-02-17 | 1998-04-01 | Pharming B.V. | Séquences d'ADN pour diriger des protéines vers les glandes mammaires, afin d'être secrétées efficacement |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US6291161B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
US6680192B1 (en) | 1989-05-16 | 2004-01-20 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US6291160B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
WO1991000360A1 (fr) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Reactifs bispecifiques pour le traitement du sida |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
ATE169030T1 (de) | 1990-06-28 | 1998-08-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
US5304389A (en) | 1991-06-18 | 1994-04-19 | Mitsubishi Kasei Corporation | Non-hygroscopic icing composition |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (fr) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methode de production de chainons de paires de liaison specifique |
WO1992005793A1 (fr) | 1990-10-05 | 1992-04-16 | Medarex, Inc. | Immunostimulation ciblee induite par des reactifs bispecifiques |
ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
AU660297B2 (en) | 1990-11-09 | 1995-06-22 | Stephen D. Gillies | Cytokine immunoconjugates |
US6106835A (en) | 1991-04-19 | 2000-08-22 | Tanox, Inc. | Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators |
AP257A (en) | 1991-04-26 | 1993-06-03 | Surface Active Ltd | A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy. |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2110799A1 (fr) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Fragments d'anticorps d'origine microbienne, et conjugues |
WO1993006217A1 (fr) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab')¿2? |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
AU665221B2 (en) | 1991-12-02 | 1995-12-21 | Cambridge Antibody Technology Limited | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
ATE239506T1 (de) | 1992-03-05 | 2003-05-15 | Univ Texas | Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren |
CA2115811A1 (fr) | 1993-02-17 | 1994-08-18 | Claus Krebber | Methode de selection in vivo de proteines fixatrices de ligands |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
WO1996013583A2 (fr) | 1994-10-20 | 1996-05-09 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Hetero-association ciblee de proteines recombinees et de complexes fonctionnels |
EP1990409A3 (fr) | 1999-07-20 | 2011-05-18 | MorphoSys AG | Bactériophage |
US7094571B2 (en) | 2000-10-27 | 2006-08-22 | The Board Of Regents Of The University Of Texas System | Combinatorial protein library screening by periplasmic expression |
US7083945B1 (en) | 2000-10-27 | 2006-08-01 | The Board Of Regents Of The University Of Texas System | Isolation of binding proteins with high affinity to ligands |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
WO2011080765A2 (fr) * | 2010-01-04 | 2011-07-07 | Indian Immunologicals Limited | Diabody bivalent humain recombinant contre le virus de la rage et utilisation de celui-ci |
CN101812130B (zh) * | 2010-05-06 | 2012-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗狂犬病毒糖蛋白中和性抗体(RVFab5) |
CN101812131B (zh) * | 2010-05-06 | 2012-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗狂犬病毒糖蛋白中和性抗体(RVFab8) |
CN101812132B (zh) * | 2010-05-06 | 2012-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗狂犬病毒糖蛋白中和性抗体(RVFab3) |
JP5868549B2 (ja) * | 2012-05-24 | 2016-02-24 | マウントゲイト グループ リミテッド | 狂犬病感染の予防および治療に関する組成物および方法 |
-
2012
- 2012-05-24 JP JP2015512986A patent/JP5868549B2/ja active Active
- 2012-05-24 IN IN2831KON2014 patent/IN2014KN02831A/en unknown
- 2012-05-24 MX MX2014014412A patent/MX369626B/es active IP Right Grant
- 2012-05-24 BR BR112014029274-4A patent/BR112014029274B1/pt active IP Right Grant
- 2012-05-24 SG SG11201408330XA patent/SG11201408330XA/en unknown
- 2012-05-24 US US14/402,644 patent/US9290564B2/en active Active
- 2012-05-24 WO PCT/CN2012/076012 patent/WO2013174003A1/fr active Application Filing
- 2012-05-24 CN CN201280074853.9A patent/CN104603149B/zh active Active
- 2012-05-24 EP EP12877555.8A patent/EP2855521A4/fr active Pending
- 2012-05-24 EP EP19156037.4A patent/EP3508497A1/fr active Pending
- 2012-05-24 KR KR1020147036192A patent/KR101937733B1/ko active IP Right Grant
-
2014
- 2014-11-24 PH PH12014502628A patent/PH12014502628B1/en unknown
-
2015
- 2015-11-02 HK HK15110797.7A patent/HK1210187A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP3508497A1 (fr) | 2019-07-10 |
HK1210187A1 (en) | 2016-04-15 |
IN2014KN02831A (fr) | 2015-05-08 |
PH12014502628A1 (en) | 2015-01-26 |
JP5868549B2 (ja) | 2016-02-24 |
PH12014502628B1 (en) | 2015-01-26 |
US20150110781A1 (en) | 2015-04-23 |
CN104603149B (zh) | 2017-06-30 |
CN104603149A (zh) | 2015-05-06 |
KR101937733B1 (ko) | 2019-01-11 |
KR20150016590A (ko) | 2015-02-12 |
US9290564B2 (en) | 2016-03-22 |
WO2013174003A1 (fr) | 2013-11-28 |
MX369626B (es) | 2019-11-13 |
JP2015525206A (ja) | 2015-09-03 |
MX2014014412A (es) | 2015-07-21 |
BR112014029274A2 (pt) | 2018-04-24 |
EP2855521A4 (fr) | 2016-03-02 |
BR112014029274B1 (pt) | 2022-02-15 |
EP2855521A1 (fr) | 2015-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408330XA (en) | Compositions and methods related to prevention and treatment of rabies infection | |
SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201809064QA (en) | Chimeric neurotoxins | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201407233RA (en) | Ethylene oligomerization process | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
SG11201406977TA (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
SG11201407774XA (en) | Conversion of biomass | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201407265RA (en) | Novel ha binding agents | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity | |
SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
SG11201809793UA (en) | Tl1a antibodies and uses thereof | |
SG11201901597UA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies |